Loading
Trastuzumab deruxtecan shrank tumours in half of patients with HER2-positive gastric cancer that had progressed after trastuzumab, compared with 14 percent on chemotherapy, and lengthened survival by over four months.
Randomised phase 2 trial in Japan and South Korea of 187 patients with HER2-positive advanced gastric or junctional adenocarcinoma after at least two prior regimens including trastuzumab, randomised 2:1 to trastuzumab deruxtecan 6.4 mg/kg or physician's choice of irinotecan or paclitaxel.
Objective response was 51 versus 14 percent and median overall survival 12.5 versus 8.4 months (hazard ratio 0.59); interstitial lung disease occurred in 10 percent, with myelosuppression as the other main toxicity.
Trastuzumab deruxtecan is the standard second- or third-line treatment for HER2-positive gastric cancer, later confirmed against ramucirumab-paclitaxel in DESTINY-Gastric04.
Shares Trastuzumab deruxtecan, Trastuzumab, New England Journal of Medicine.
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Trastuzumab.
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Trastuzumab.
Shares HER2-positive gastric cancer, Trastuzumab.
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Trastuzumab.
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Trastuzumab.
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan.
Shares HER2-positive gastric cancer, Trastuzumab.